Dr. Albert S. Malcolm
Claim this profileDayton Veterans Affairs Medical Center
Studies Multiple Myeloma
Studies Plasma Cell Neoplasms
3 reported clinical trials
7 drugs studied
Area of expertise
1Multiple Myeloma
Stage III
Stage IV
2Plasma Cell Neoplasms
Stage III
Stage IV
Affiliated Hospitals
Clinical Trials Albert S. Malcolm is currently running
Lenalidomide + Dexamethasone +/- Daratumumab
for Multiple Myeloma
This phase III trial studies how well lenalidomide and dexamethasone works with or without daratumumab in treating patients with high-risk smoldering myeloma. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as daratumumab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Giving lenalidomide and dexamethasone with daratumumab may work better in treating patients with smoldering myeloma.
Recruiting2 awards Phase 312 criteria
Lenalidomide +/- Daratumumab
for Multiple Myeloma
Patients are enrolled to screening (Reg Step 1) prior to or after ASCT but prior to Reg Step 2. Patients are followed until they will begin Maintenance and then registered to Reg Step 2 (first randomization). Patients are randomized between Lenalidomide for 2 years and Lenalidomide + Daratumumab/rHuPH20. After 2 years of Maintenance, MRD is assessed to guide further therapy. MRD-positive patients will continue with the assigned treatment. MRD-negative patients will be further randomized (Reg Step 3) to either continue or discontinue the assigned treatment. Patients are treated for up to 7 years from Step 2 reg and followed for up to 15 years.
Recruiting2 awards Phase 317 criteria
More about Albert S. Malcolm
Clinical Trial Related5 years of experience running clinical trials · Led 3 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Albert S. Malcolm has experience with
- Lenalidomide
- Daratumumab/rHuPH20
- Venetoclax
- Ibrutinib
- Obinutuzumab
- Dexamethasone
Breakdown of trials Albert S. Malcolm has run
Multiple Myeloma
Plasma Cell Neoplasms
Chronic B-Cell Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Albert S. Malcolm specialize in?
Albert S. Malcolm focuses on Multiple Myeloma and Plasma Cell Neoplasms. In particular, much of their work with Multiple Myeloma has involved Stage III patients, or patients who are Stage IV.
Is Albert S. Malcolm currently recruiting for clinical trials?
Yes, Albert S. Malcolm is currently recruiting for 2 clinical trials in Dayton Ohio. If you're interested in participating, you should apply.
Are there any treatments that Albert S. Malcolm has studied deeply?
Yes, Albert S. Malcolm has studied treatments such as Lenalidomide, Daratumumab/rHuPH20, Venetoclax.
What is the best way to schedule an appointment with Albert S. Malcolm?
Apply for one of the trials that Albert S. Malcolm is conducting.
What is the office address of Albert S. Malcolm?
The office of Albert S. Malcolm is located at: Dayton Veterans Affairs Medical Center, Dayton, Ohio 45428 United States. This is the address for their practice at the Dayton Veterans Affairs Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.